Cyclin-dependent kinase 4 (Cdk4) represents a prime target for the treatment of cancer because most human cancers are characterized by overexpression of its activating partner cyclin D1, loss of the natural Cdk4-specific inhibitor p16, or mutation(s) in Cdk4's catalytic subunit.
Publication type:Research Problem
Published:
Language:English
Licence:
CC BY 4.0
Peer Reviews (This Version): (0)
Red flags:
(0)
Actions
Download:
Sign in for more actionsSections
Research topics above this in the hierarchy
Funders
No sources of funding have been specified for this Research Problem.
Conflict of interest
This Research Problem does not have any specified conflicts of interest.